Want to see IN:SOLARA full AI Analyst Report?
SOLARA Stock Chart & Stats
₹490.35
₹13.05(2.65%)
At close: 4:00 PM EDT
₹490.35
₹13.05(2.65%)
Day’s Range― - ―
52-Week Range₹422.85 - ₹774.00
Previous CloseN/A
Volume579.03K
Average Volume (3M)34.89K
Market Cap
₹35.61B
Enterprise Value₹26.83K
Total Cash (Recent Filing)₹533.40M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.45%
Share Statistics
EPS (TTM)-0.56
Shares Outstanding48,070,286
10 Day Avg. Volume43,574
30 Day Avg. Volume34,887
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.50
Price to Sales (P/S)1.37
P/FCF Ratio211.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31.4
Revenue Forecast (FY)₹17.95B
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe return to topline growth indicates that Solara regained commercial momentum after a period of stagnation. Continued API demand and higher volumes could improve operating leverage, strengthen customer relationships, and support earnings recovery over the next several quarters.
Lower LeverageThe substantial reduction in leverage improves Solara’s financial flexibility and lowers balance-sheet pressure. A stronger equity base and lower debt burden can support investment in capacity and development while giving the company more resilience through uneven pharmaceutical cycles.
Operating Profit RecoveryThe return to positive operating profit suggests the business has recovered some operational footing after the FY2024 disruption. If maintained, this improvement could provide a foundation for rebuilding earnings, funding operations internally, and converting revenue growth into more durable profitability.
Bears Say
Persistent Net LossDespite improved operating performance, Solara has not yet restored bottom-line profitability. The continuing net loss limits internally generated capital, weakens returns to shareholders, and indicates that the company’s earnings power remains fragile over the medium term.
Margin VolatilitySuch a sharp gross-margin contraction points to unstable economics across pricing, product mix, or costs. Persistent volatility makes earnings less predictable, reduces the benefit of revenue growth, and complicates planning for capacity, investment, and sustainable shareholder returns.
Weak Cash GenerationThe steep decline in free cash flow shows that accounting recovery has not translated into comparable cash generation. Lower cash availability can restrict investment and debt reduction, while the historical volatility increases uncertainty around Solara’s ability to fund growth consistently.
Solara Active Pharma Sciences Ltd. News
SOLARA FAQ
What was Solara Active Pharma Sciences Ltd.’s price range in the past 12 months?
Solara Active Pharma Sciences Ltd. lowest stock price was ₹422.85 and its highest was ₹774.00 in the past 12 months.
What is Solara Active Pharma Sciences Ltd.’s market cap?
Solara Active Pharma Sciences Ltd.’s market cap is ₹35.61B.
When is Solara Active Pharma Sciences Ltd.’s upcoming earnings report date?
Solara Active Pharma Sciences Ltd.’s upcoming earnings report date is Nov 11, 2026 which is in 51 days.
How were Solara Active Pharma Sciences Ltd.’s earnings last quarter?
Solara Active Pharma Sciences Ltd. released its earnings results on Jul 23, 2026. The company reported ₹3.52 earnings per share for the quarter.
Is Solara Active Pharma Sciences Ltd. overvalued?
According to Wall Street analysts Solara Active Pharma Sciences Ltd.’s price is currently Overvalued.
Does Solara Active Pharma Sciences Ltd. pay dividends?
Solara Active Pharma Sciences Ltd. pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.45%. See more information on Solara Active Pharma Sciences Ltd. dividends here
What is Solara Active Pharma Sciences Ltd.’s EPS estimate?
Solara Active Pharma Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solara Active Pharma Sciences Ltd. have?
Solara Active Pharma Sciences Ltd. has 48,070,286 shares outstanding.
What happened to Solara Active Pharma Sciences Ltd.’s price movement after its last earnings report?
Solara Active Pharma Sciences Ltd. reported an EPS of ₹3.52 in its last earnings report. Following the earnings report the stock price went down -2.12%.
Which hedge fund is a major shareholder of Solara Active Pharma Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SOLARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solara Active Pharma Sciences Ltd.
Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing, processing, sale, import, and export of these essential drug components. The company's extensive product range includes APIs designed for a wide spectrum of therapeutic applications, such as anesthetics, antibiotics, antivirals, cardiovascular agents, central nervous system treatments, anti-inflammatory drugs, and treatments for metabolic disorders like type-II diabetes, among numerous other specialized categories. Beyond its core product offerings, Solara also delivers specialized contract research and manufacturing services (CRAMS) for APIs. These services encompass custom development and manufacturing, analytical support, impurity synthesis, and comprehensive regulatory assistance. The company maintains a significant international presence, exporting its products and conducting operations across diverse global regions, including the Asia Pacific, Europe, North America, and South America. Headquartered in Chennai, India, Solara Active Pharma Sciences Limited was established in 2017. Initially known as SSL Pharma Sciences Limited, the company adopted its current name in March of the same year.
Technical Analysis
Granules India Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Strides Pharma Science Ltd
―
Unichem Laboratories Limited
―